Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats

Nephrology

Volumn 17, Issue 4, 2012, Pages 380-389

  Yu, Wei Min ^a   Wang, Huan ^b   Ren, Xiao Jun ^a   Liu, Jun Ping ^c   Wang, Jian Ying ^c  

^a Shanxi Dayi Hospital   (China)

^b Traditional Chinese Medicine of Shanxi Province   (China)

^c SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

diabetic nephropathy; inflammation; leflunomide

Indexed keywords

ALBUMIN; CREATININE; ECTODYSPLASIN A; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG EFFECT; ELECTRON MICROSCOPY; GENE EXPRESSION; GENE SEQUENCE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY HYPERTROPHY; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; CREATININE; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INFLAMMATION MEDIATORS; ISOXAZOLES; KIDNEY; MALE; NEPHRECTOMY; NF-KAPPA B; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860130794     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2012.01563.x     Document Type: Article

References (30)

1. Gross IL, de Azevedo MJ, Silveiro SP, et al,. Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-76. (Pubitemid 40095801)
2. Wright J, Vardhan A,. Review: The problem of diabetic nephropathy and practical prevention of its progression. Br. J. Diabetes Vasc. Dis. 2008; 8: 272-7.
3. Schrijvers BF, De Vriese AS, Flyvbjerg A,. From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocrine 2004; 25: 971-1010. (Pubitemid 39657775)
4. Navarro-González JF, Mora-Fernández C,. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 2008; 19: 433-42. (Pubitemid 351355386)
5. Mora C, Navaho JF,. Inflammation and diabetic nephropathy. Curr. Diab. Rep. 2006; 6: 463-8. (Pubitemid 44896406)
6. Fornoni A, Tejada T,. Role of inflammation in diabetic nephropathy. Curr. Diabetes Rev. 2008; 4: 10-17. (Pubitemid 351216880)
7. Goldberg RB,. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab 2009; 94: 3171-82.
8. Bohlender JM, Franke S, Stein G, Wolf G,. Advanced glycation end products and the kidney. Am. J. Physiol. Renal Physiol. 2005; 289: F645-9.
9. Vieitez P, Gõmez O, Uceda ER, Vera ME, Molina-Holgado E,. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. J. Renin Angiotensin Aldosterone Syst. 2008; 9: 96-102. (Pubitemid 351998217)
10. Xu X, Shen J, Mall JW, et al,. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: Mechanisms of action. Biochem. Pharmacol. 1999; 58: 1405-13. (Pubitemid 29438642)
11. Migita K, Miyashita T, Maeda Y, et al,. An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes. Rheumatology 2005; 44: 443-8. (Pubitemid 41511131)
12. Siemasko K, Chong AS, Jäck HM, Gong H, Williams JW, Finnegan A,. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol. 1998; 160: 1581-8. (Pubitemid 28106441)
13. Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M,. Active leflunomide metabolite inhibits interleukin 1β, tumour necrosis factor α, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann. Rheum. Dis. 2003; 62: 440-43. (Pubitemid 36469736)
14. Manna SK, Mukhopadhyay A, Aggarwal BB,. Leflunomide suppresses TNF-induced cellular responses: Effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J. Immunol. 2000; 165: 5962-9.
15. Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC,. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: An open label tria1. Ann. Rheum. Dis. 2006; 65: 417-18. (Pubitemid 43268242)
16. Maddison P, Kiely P, Kirkham B, et al,. Leflunomide in rheumatoid arthritis: Recommendations through a process of consensus. Rheumatology 2005; 44: 280-86. (Pubitemid 40361281)
17. Lou T, Wang C, Chen Z, et al,. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. Nephrology 2006; 11: 113-16.
18. Sobhani K, Garrett DA, Liu DP, Rainey PM,. A rapid and simple high-performance liquid chromatography assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant recipients. Am. J. Clin. Pathol. 2010; 133: 454-7.
19. Jensen EB, Gundersen HJ, Osterby R,. Determination of membrane thickness distribution from orthogonal intercepts. J. Microsc. 1979; 115: 19-33. (Pubitemid 10225698)
20. Liou HC,. Regulation of the immune system by NF-kappaB and IkappaB[J]. Mol. Biol. 2002; 35: 537-46.
21. Brasier AR,. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc. Res. 2010; 86: 211-18.
22. Navarro J, Milena F, Mora C, et al,. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: Relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int. Suppl. 2005; 99: S98-102.
23. Kalantarinia K, Awad AS, Siragy HM,. Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003; 64: 1208-13. (Pubitemid 37153785)
24. Navarro JF, Mora C, Muros M, García J,. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol. Dial. Transplant. 2006; 21: 3428-34. (Pubitemid 44817091)
25. Sassy-Prigent C, Heudes D, Mandet C, et al,. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000; 49: 466-75. (Pubitemid 30131794)
26. Chow FY, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH,. Macrophages in mouse type 2 diabetic nephropathy: Correlation with diabetic state and progressive renal injury. Kidney Int. 2004; 65: 116-28. (Pubitemid 38037496)
27. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH,. Macrophages in streptozotocin-induced diabetic nephropathy: Potential role in renal fibrosis. Nephrol. Dial. Transplant. 2004; 19: 2987-96. (Pubitemid 40057619)
28. Banba N, Nakamura T, Matsumura M, et al,. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 2000; 58: 684-90. (Pubitemid 30620017)
29. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB,. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J. Am. Soc. Nephrol. 2002; 13: 894-902. (Pubitemid 34274085)
30. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH,. Monocyte chemoatractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006; 69: 73-80. (Pubitemid 43117741)